These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1142 related items for PubMed ID: 17667143

  • 1. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS, Kim SH, Choi YM.
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [Abstract] [Full Text] [Related]

  • 2. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG, Kim JH, Lee DO, Kim H, Kim JY, Suh CS, Kim SH, Choi YM.
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [Abstract] [Full Text] [Related]

  • 3. Genetic polymorphisms of OPG, RANK, and ESR1 and bone mineral density in Korean postmenopausal women.
    Choi JY, Shin A, Park SK, Chung HW, Cho SI, Shin CS, Kim H, Lee KM, Lee KH, Kang C, Cho DY, Kang D.
    Calcif Tissue Int; 2005 Sep; 77(3):152-9. PubMed ID: 16151677
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Gene-gene interactions in RANK/RANKL/OPG system influence bone mineral density in postmenopausal women.
    Zupan J, Mencej-Bedrac S, Jurković-Mlakar S, Prezelj J, Marc J.
    J Steroid Biochem Mol Biol; 2010 Jan; 118(1-2):102-6. PubMed ID: 19896533
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women.
    Markatseli AE, Hatzi E, Bouba I, Georgiou I, Challa A, Tigas S, Tsatsoulis A.
    Maturitas; 2011 Oct; 70(2):188-93. PubMed ID: 21840657
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B, Hjelmborg JV, Kostenuik P, Stilgren LS, Kyvik K, Adamu S, Brixen K, Langdahl BL.
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [Abstract] [Full Text] [Related]

  • 11. Association of TNFSF11 gene promoter polymorphisms with bone mineral density in postmenopausal women.
    Mencej S, Prezelj J, Kocijancic A, Ostanek B, Marc J.
    Maturitas; 2006 Oct 20; 55(3):219-26. PubMed ID: 16730419
    [Abstract] [Full Text] [Related]

  • 12. The effects of C161-->T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-gamma gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women.
    Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW.
    Am J Obstet Gynecol; 2005 Apr 20; 192(4):1087-93. PubMed ID: 15846185
    [Abstract] [Full Text] [Related]

  • 13. Association of the osteoprotegerin gene polymorphisms with bone mineral density in postmenopausal women.
    Arko B, Prezelj J, Kocijancic A, Komel R, Marc J.
    Maturitas; 2005 Jul 16; 51(3):270-9. PubMed ID: 15978970
    [Abstract] [Full Text] [Related]

  • 14. Changes in RANKL/OPG/RANK gene expression in peripheral mononuclear cells following treatment with estrogen or raloxifene.
    Bashir A, Mak YT, Sankaralingam S, Cheung J, McGowan NW, Grigoriadis AE, Fogelman I, Hampson G.
    Steroids; 2005 Dec 01; 70(13):847-55. PubMed ID: 16005483
    [Abstract] [Full Text] [Related]

  • 15. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women.
    Mencej-Bedrač S, Preželj J, Marc J.
    Maturitas; 2011 Jul 01; 69(3):263-7. PubMed ID: 21411255
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of RANK/RANKL/OPG gene polymorphisms in aggressive periodontitis.
    Soedarsono N, Rabello D, Kamei H, Fuma D, Ishihara Y, Suzuki M, Noguchi T, Sakaki Y, Yamaguchi A, Kojima T.
    J Periodontal Res; 2006 Oct 01; 41(5):397-404. PubMed ID: 16953816
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Osteoprotegerin gene polymorphism and therapeutic response to alendronate in postmenopausal women with osteoporosis].
    Wang C, He JW, Qin YJ, Zhang H, Hu WW, Liu YJ, Zhang ZL.
    Zhonghua Yi Xue Za Zhi; 2009 Nov 17; 89(42):2958-62. PubMed ID: 20137703
    [Abstract] [Full Text] [Related]

  • 19. Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study.
    Assmann G, Koenig J, Pfreundschuh M, Epplen JT, Kekow J, Roemer K, Wieczorek S.
    J Rheumatol; 2010 May 17; 37(5):900-4. PubMed ID: 20231205
    [Abstract] [Full Text] [Related]

  • 20. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
    Zheng H, Wang C, He JW, Fu WZ, Zhang ZL.
    Pharmacogenet Genomics; 2016 Jan 17; 26(1):12-9. PubMed ID: 26426211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.